In 2006, the research-and-development arm of Pliva was acquired by GlaxoSmithKline, which has ample resources for clinical trials, but the company has not commercialized the peptide
Intellectual Property and Clinical Research Trends: Recent global patent trends reflect the growing interest in GLP-1 across the food space, particularly in boosting GLP-1 secretion, appetite regulation, and diabetes control
ActiveFX delivers the following advantages: Minimal downtime Longlasting results Outpatient appointment Areas of Treatment with ActiveFX ActiveFX is used to treat a wide variety of skin issues, including age spots, oversized pores, scars, pigmentation problems, sagginess, wrinkles, and loss of elasticity
Taurine attenuates bilirubin-induced neurotoxicity in the auditory system in neonatal guinea pigs